ReviewOcular oncology and pathology2015
Uveal Melanoma Metastasis Models.
Review in Ocular oncology and pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Novel CRISPR-Cas9 BAP1 knockout pre-clinical tumor model recapitulates human melanoma tumorigenesis and immune evolution.Communications biology · 2026Article
- Multi-responsive nanocomposite hydrogel for synergistic photothermal-chemotherapy to prevent postoperative recurrence and metastasis of uveal melanoma.Materials today. Bio · 2025Article
- Establishment of patient-derived xenografts of retinoblastoma and choroidal melanoma on the avian chorioallantoic membrane.Indian journal of ophthalmology · 2023Article
- Animal Models of Uveal Melanoma.Annals of eye science · 2022Article
- Mouse models of uveal melanoma: Strengths, weaknesses, and future directions.Pigment cell & melanoma research · 2020Review
- Visualization and Quantitative 3D Analysis of Intraocular Melanoma and Its Vascularization in a Hamster Eye.International journal of molecular sciences · 2018Article
- Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines.OncoTargets and therapy · 2018Article
- Embryonic Zebrafish: Different Phenotypes after Injection of Human Uveal Melanoma Cells.Ocular oncology and pathology · 2015Review
- Animal Eye Models for Uveal Melanoma.Ocular oncology and pathology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Metastatic disease is the leading cause of death among patients with uveal melanoma. Treatment options for patients with clinically disseminated disease are usually unsuccessful. In vitro and in vivo models are important tools to investigate the pathogenesis of metastatic uveal melanomas and develop treatments for the metastases. In vitro experimental approaches focusing on cell invasion/migration which mimic the steps of the complex metastatic process may also be used for the identification of potential anti-invasion/migration drugs that may inhibit the spreading of tumor cells or the development of metastases. The effects of these drugs must subsequently be confirmed in reliable in vivo models before entering the clinical trial phase. Several models of intraocular melanoma with metastases in rodents and rabbits are currently being used. Most experimental models of uveal melanoma metastases require injection or implantation of melanoma cells into orthotopic locations, including into the liver, spleen, tail vein, or the left ventricle of the heart, in order to mimic the metastatic process.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.